切换至 "中华医学电子期刊资源库"

中华胸部外科电子杂志 ›› 2015, Vol. 02 ›› Issue (02) : 83 -87. doi: 10.3877/cma.j.issn.2095-8773.2015.02.002

所属专题: 文献

述评

食管癌术前放化疗与术前化疗:孰优孰劣?
傅剑华1,()   
  1. 1. 510060 广州,中山大学肿瘤防治中心;广东省食管癌研究所
  • 收稿日期:2015-03-04 出版日期:2015-05-28
  • 通信作者: 傅剑华

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal cancer: which is better?

Jianhua FU1,()   

  1. 1. Department of Thoracic Oncology, Cancer Center, Sun Yat-Sen University; Guangdong Esophageal Cancer Institute, Guangzhou 510060, China
  • Received:2015-03-04 Published:2015-05-28
  • Corresponding author: Jianhua FU
  • About author:
    Corresponding author: Fu Jian-hua, Email:
引用本文:

傅剑华. 食管癌术前放化疗与术前化疗:孰优孰劣?[J]. 中华胸部外科电子杂志, 2015, 02(02): 83-87.

Jianhua FU. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal cancer: which is better?[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2015, 02(02): 83-87.

中国是食管癌高发国家,外科手术是我国食管癌的主要治疗手段,但单纯手术对于中晚期食管癌的治疗效果不尽如人意。为了提高食管癌的疗效,国内外学者进行了多种综合治疗模式的探索,包括术前放疗、术前化疗、术后放疗等,其中术前新辅助治疗的模式特别引人关注。术前新辅助治疗,包括术前放化疗和术前化疗,尤其是前者有望提高食管癌患者的预后。该文拟对以手术为主的食管癌新辅助治疗的循证医学证据进行综述。

In China, the incidence of esophageal cancer is rather high. For patients with resectable esophageal cancer, surgery is the standard treatment. However, the overall survival of patients with locally advanced esophageal cancer remains low, which highlights why further advances of combined therapy are so desperately needed. Among the multimodality treatments, the most promising strategy to improve the prognosis of advanced esophageal cancer is preoperative chemoradiation followed by surgery. The aim of this article is to provide a complete review of the current status of esophageal cancer treatment with the addition of neoadjuvant chemotherapy and radiotherapy to the surgical management of resectable disease.

[1]
平育敏,张毓德,杜喜群,等. 食管癌和贲门癌20000例外科治疗经验[R]. 中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集,2005:167-171.
[2]
邵令方,高宗人,许金良,等. 食管癌和贲门癌的外科治疗15707例总结——附河南省食管癌的防治研究概况[R]. 中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集,2005:40-45.
[3]
Bhansali M, Vaidya J, Bhatt R, et al. Chemotherapy for carcinoma of the oesophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies[J]. Ann Oncol, 1996, 7(4): 355-359.
[4]
Fok M, McShane J, Law SYK, et al. Prospective randomised study on radiotherapy and surgery in the treatment of oesophageal carcinoma[J]. Asian J Surg, 1994, 17: 223-229.
[5]
Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma [J]. Cochrane Database Syst Rev, 2005, 4:CD001799.
[6]
Sutton P, Clark P. Neo-adjuvant treatment for oesophageal cancer[J]. GI Cancer, 2000, 11(3): 231-238.
[7]
Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer[J]. J Surg Oncol,2010,101(4):299-304.
[8]
Berger AC, Farma J, Scott WJ, et al.Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival[J]. J Clin Oncol, 2005,23(19):4330-4337.
[9]
Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report[J]. J Clin Oncol,1993,11(6): 1118-1123.
[10]
Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer[J]. Ann Surg, 2010,252(5):744-749.
[11]
Schlag P. Randomized trial of preoperative chemothe5rapy for squamous cell carcinoma of the esophagus[J]. Arch Surg, 1992, 127(12): 1446-1450.
[12]
Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial[J]. J Thorac Cardiovasc Surg, 1997, 114(2): 210-217.
[13]
Kelsen D, Ginsber R, Pajak T, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer[J]. N Engl J Med, 1998, 339(27): 1979-1984.
[14]
Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma[J]. Cancer, 2001, 91(11): 2165-2174.
[15]
Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial[J]. Lancet, 2002, 359: 1727-1734.
[16]
Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer[J]. Am J Surg, 2002, 183(3): 274-279.
[17]
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis[J]. Lancet Oncol, 2011,12(7):681-692.
[18]
Polee MB, Tilanus HW, Eskens FA, et al. Phase Ⅱ study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus[J]. Ann Oncol, 2003,14(8):1253-1257.
[19]
Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer[J]. Br J Surg, 2001,88(3): 338-356.
[20]
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012,366(22):2074-2084.
[21]
Yang H, Fu JH, Liu MZ, et al. A phase Ⅲ clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus[J]. J Clin Oncol, 2014, 32:5s (suppl, abstr TPS4146).
[22]
杨弘,傅剑华,刘孟忠,等.术前放化疗并手术与单纯手术治疗局部晚期食管鳞癌的多中心随机对照临床研究[J] . 中华医学杂志,2012,92(15):1028-1033.
[23]
Stiles BM, Nasar A, Paul S, et al. Preoperative chemoradiation versus preoperative chemotherapy alone for esophageal cancer: higher response rates but equivalent survival[J]. J Clin Oncol,2014, 32:5s(suppl; abstr 4071).
[24]
Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer: final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J]. J Clin Oncol, 2014,32(23):2416-2422.
[25]
中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南[M]. 北京:中国协和医科大学出版社,2011.
[1] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2] 李辉, 吴奇, 张子琦, 张晗, 王仿, 许鹏. 日间全膝关节置换术早期疗效及标准化流程探索[J]. 中华关节外科杂志(电子版), 2023, 17(06): 889-892.
[3] 王玲燕, 邹磊, 洪亮, 宋三兵, 付润, 熊胜男, 宋晓春. 心脏外科术后患者并发低三碘甲状腺原氨酸综合征的影响因素分析[J]. 中华危重症医学杂志(电子版), 2023, 16(05): 399-402.
[4] 刘林峰, 王增涛, 王云鹏, 钟硕, 郝丽文, 仇申强, 陈超. 足底内侧皮瓣联合甲骨皮瓣在手指V度缺损再造中的临床应用[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 480-484.
[5] 何传超, 肖治宇. 晚期肝癌综合治疗模式与策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 486-489.
[6] 李双喜, 胡宗凯, 赵静, 黄洁. 肝血管瘤治疗指征及治疗策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 504-510.
[7] 邹敏, 徐明, 吴伟强, 归明彬, 高峰. 低位直肠癌新辅助放化疗应用的焦点问题[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 363-371.
[8] 李晓东, 魏云. 冠状切口额下入路治疗前颅窝巨大脑膜瘤[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 318-319.
[9] 侯超, 潘美辰, 吴文明, 黄兴广, 李翔, 程凌雪, 朱玉轩, 李文波. 早期食管癌及上皮内瘤变内镜黏膜下剥离术后食管狭窄的危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 383-387.
[10] 单秋洁, 孙立柱, 徐宜全, 王之霞, 徐妍, 马浩, 刘田田. 中老年食管癌患者调强放射治疗期间放射性肺损伤风险模型构建及应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 388-393.
[11] 苏鹏, 吕会来, 温士旺, 黄超, 张缜, 田子强. 全腔镜下食管癌根治术围手术期呼吸系统并发症发生的危险因素分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 294-298.
[12] 曹旬旬, 费素娟. 食管癌患者肿瘤组织CXCL5和CXCR2的表达与病情和预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 299-304.
[13] 程相阵. 腹茧症9例诊治分析并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(9): 968-971.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 陈柯豫, 黄艳齐, 张玲利. 同时性多发早期食管癌及高级别上皮内瘤变的危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(05): 524-528.
阅读次数
全文


摘要